brexpiprazole   Click here for help

GtoPdb Ligand ID: 7672

Synonyms: OPC 34712 | OPC-34712 | Rxulti®
Approved drug
brexpiprazole is an approved drug (FDA (2015), EMA (2018))
Compound class: Synthetic organic
Comment: Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) [2].
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: brexpiprazole

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 76.81
Molecular weight 433.18
XLogP 5.36
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2
Isomeric SMILES O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2
InChI InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)
No information available.
Summary of Clinical Use Click here for help
In July 2015, brexpiprazole was approved by the US FDA for use in the treatment of schizophrenia in adults, and as an add-on treatment to an antidepressant medication in adults with major depressive disorder [1]. Brexpiprazole is also being investigated as a treatment for attention deficit hyperactivity disorder (ADHD). Click here to view's listing of current brexpiprazole drug trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Brexpiprazole is a partial agonist of the dopamine D2 receptor [2].
External links Click here for help